ScPhar­ma­ceu­ti­cals rais­es $90M in IPO with heart fail­ure drug on deck

ScPhar­ma­ceu­ti­cals, a com­pa­ny with a heart fail­ure drug on deck for FDA ap­proval, raised about $90 mil­lion in an IPO Fri­day, com­ing in at the low­er end of its range.

The com­pa­ny of­fered 6.4 mil­lion shares at $14 apiece.  Last month, when scPhar­ma­ceu­ti­cals filed reg­u­la­to­ry pa­per­work sig­nal­ing its in­tent to go pub­lic, the com­pa­ny was shoot­ing for a $100 mil­lion raise.

The biotech’s lead drug can­di­date is a new for­mu­la­tion of furosemide (which you may rec­og­nize as Validus Phar­ma­ceu­ti­cal’s brand­ed drug Lasix), a di­uret­ic that can treat flu­id re­ten­tion and swelling caused by con­ges­tive heart fail­ure. ScPhar­ma­ceu­ti­cal’s ver­sion of the drug is de­signed to be de­liv­ered with a wear­able de­vice at home in­stead of a hos­pi­tal IV. The idea is to re­duce the num­ber of days a pa­tient must be hos­pi­tal­ized for ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA